Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2

Απλή σελίδα τεκμηρίου
dc.contributor.authorKosmidis, P. A.en
dc.contributor.authorSyrigos, K.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBoukovinas, I.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorBacoyiannis, C.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:43:17Z
dc.date.available2015-11-24T19:43:17Z
dc.identifier.issn1791-7530-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24738
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/drug therapy/mortality/secondaryen
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBone Neoplasms/drug therapy/mortality/secondaryen
dc.subjectBrain Neoplasms/drug therapy/mortality/secondaryen
dc.subjectCarcinoma, Large Cell/diagnosis/geneticsen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapy/*mortality/secondaryen
dc.subjectCarcinoma, Squamous Cell/drug therapy/mortality/secondaryen
dc.subjectDisease Progressionen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectLiver Neoplasms/drug therapy/mortality/secondaryen
dc.subjectLung Neoplasms/drug therapy/mortality/pathologyen
dc.subjectLymphatic Metastasisen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/*drug therapy/mortality/pathologyen
dc.subjectNeoplasm Stagingen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectSmall Cell Lung Carcinoma/drug therapy/mortality/secondaryen
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.subjectVinblastine/administration & dosage/analogs & derivativesen
dc.titleVinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2en
heal.abstractAIM: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. PATIENTS AND METHODS: The patients were randomized to receive either oral vinorelbine 60 mg/m(2) on days 1, 8, 15 every 4 weeks for 4 cycles (group A) or paclitaxel 90 mg/m(2) intravenously for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B). RESULTS: Among the 74 eligible patients (36 in arm A and 38 in arm B) in arm A, two (6%) had a partial response (95% CI, 0.7-18.7) and 5 (14%) had stable disease (95% CI, 4.7-29.5). In arm B, five (13%) had a partial response (95% CI, 4.4-28.1) and 7 (18%) had stable disease (95% CI, 7.7-34.3). No significant difference was found in terms of clinical benefit between the two groups after two cycles of treatment except for appetite in favour of paclitaxel (p=0.01). Median survival was 3.1 months (95% CI, 2.2-4.0) for arm A and 5.1 months (95% CI, 2.7-7.6) for arm B (p=0.95). Toxicity was mild and only alopecia was more profound in the patients of arm B (p=0.008). CONCLUSION: No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/22213304-
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2012-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ